Medicare Part D coverage · sucroferric oxyhydroxide · RxCUI 1484296
sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro]
Per the CMS 2026 Part D formulary file, sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro] is covered by 267 Medicare Part D plans (5.3% of enrollable products), averaging Tier 4.4, with prior authorization required on 7.1% of covering formularies.
- 5.3%
- Plan coverage
- 267
- Plans covering
- T4.4
- Avg tier
- 7.1%
- Prior auth required
What the CMS Formulary Data Shows for sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro]
Per the CMS 2026 Part D formulary file, sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro] (RxNorm concept RXCUI 1484296, generic name sucroferric oxyhydroxide) appears on 28 distinct formulary files spanning 267 Medicare Part D plan offerings - 5.3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.4.
Real-world access to sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro] depends on utilization management as much as tier placement: 7.1% of covering formularies require prior authorization. 0% require step therapy. 7.1% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 36,082 Part D beneficiaries filled sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro] in 2023, with total plan-and-beneficiary spending of $465,812,435 and an average per-beneficiary annual cost of $12,909.83. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro] today.
Coverage Details
- Formularies covering
- 28
- Plans covering
- 267
- Coverage rate
- 5.3%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 7.1% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 7.1% of formularies
2023 Medicare Spending
- Beneficiaries
- 36,082
- Total spending
- $465,812,435
- Avg per beneficiary
- $12,909.83
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro]
100 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Provider Partners Pennsylvania Community Plan (HMO I-SNP) | Provider Partners Health Plan OF Pennsylvania, Inc | T1 | No | $0 | PA |
| Provider Partners North Carolina Community Plan (HMO I-SNP) | Provider Partners Health Plan OF North Carolina | T1 | No | $0 | NC |
| Provider Partners Indiana Community Plan (HMO I-SNP) | Provider Partners Health Plan OF Indiana | T1 | No | $0 | IN |
| Provider Partners Missouri Community Plan (HMO I-SNP) | Provider Partners Health Plan OF Missouri, Inc. | T1 | No | $0 | MO |
| Tufts Health One Care (HMO D-SNP) | Tufts Health Public Plans, Inc. | T1 | No | $0 | MA |
| Tufts Health One Care CW (HMO D-SNP) | Tufts Health Public Plans, Inc. | T1 | No | $0 | MA |
| Tufts Health Plan Senior Care Options (HMO D-SNP) | Tufts Associated Health Maintenance Organization | T1 | No | $0 | MA |
| Tufts Health Plan Senior Care Options CW (HMO D-SNP) | Tufts Associated Health Maintenance Organization | T1 | No | $0 | MA |
| Provider Partners Texas Advantage Plan (HMO I-SNP) | Provider Partners Health Plan OF Texas, Inc. | T1 | No | $4.80 | TX |
| Provider Partners Illinois Advantage Plan (HMO I-SNP) | Provider Partners Health Plan OF Illinois | T1 | No | $15.20 | IL |
| Provider Partners Pennsylvania Advantage Plan (HMO I-SNP) | Provider Partners Health Plan OF Pennsylvania, Inc | T1 | No | $32.70 | PA |
| Provider Partners Pennsylvania Essential Plan (HMO I-SNP) | Provider Partners Health Plan OF Pennsylvania, Inc | T1 | No | $32.70 | PA |
| Provider Partners North Carolina Advantage Plan (HMO I-SNP) | Provider Partners Health Plan OF North Carolina | T1 | No | $36.20 | NC |
| Provider Partners North Carolina Essential Plan (HMO I-SNP) | Provider Partners Health Plan OF North Carolina | T1 | No | $36.20 | NC |
| Provider Partners Indiana Advantage Plan (HMO I-SNP) | Provider Partners Health Plan OF Indiana | T1 | No | $38.40 | IN |
| Provider Partners Indiana Essential Plan (HMO I-SNP) | Provider Partners Health Plan OF Indiana | T1 | No | $38.40 | IN |
| Provider Partners Kentucky Advantage Plan (HMO I-SNP) | Provider Partners Health Plan OF Kentucky | T1 | No | $38.40 | KY |
| Provider Partners Missouri Advantage Plan (HMO I-SNP) | Provider Partners Health Plan OF Missouri, Inc. | T1 | No | $43.00 | MO |
| Provider Partners Missouri Essential Plan (HMO I-SNP) | Provider Partners Health Plan OF Missouri, Inc. | T1 | No | $43.00 | MO |
| Prominence Plus (HMO) | Prominence Healthfirst | T3 | No | $0 | NV |
Show the next 30 plans
| Prominence Plus (HMO) | Prominence Healthfirst | T3 | No | $0 | NV |
| Prominence Dual (HMO D-SNP) | Prominence Healthfirst | T3 | No | $0 | NV |
| Prominence Dual (HMO D-SNP) | Prominence Healthfirst | T3 | No | $0 | NV |
| Prominence Giveback (HMO) | Prominence Healthfirst | T3 | No | $0 | NV |
| Prominence Plus (HMO) | Prominence Healthfirst OF Florida Inc | T3 | No | $0 | FL |
| Prominence Giveback (HMO) | Prominence Healthfirst OF Florida Inc | T3 | No | $0 | FL |
| Prominence Plus (HMO) | Prominence Healthfirst OF Texas | T3 | No | $0 | TX |
| Prominence Plus (HMO) | Prominence Healthfirst OF Texas | T3 | No | $0 | TX |
| Prominence Dual (HMO D-SNP) | Prominence Healthfirst OF Texas | T3 | No | $0 | TX |
| Prominence Extra Help (HMO) | Prominence Healthfirst OF Texas | T3 | No | $0 | TX |
| Prominence Beyond (HMO) | Prominence Healthfirst OF Texas | T3 | No | $0 | TX |
| Prominence Giveback (HMO) | Prominence Healthfirst OF Texas | T3 | No | $0 | TX |
| Prominence Giveback (HMO) | Prominence Healthfirst OF Texas | T3 | No | $0 | TX |
| Prominence Dual (HMO D-SNP) | Prominence Healthfirst OF Texas | T3 | No | $0 | TX |
| Prominence Beyond (HMO-POS) | Prominence Healthfirst OF Texas | T3 | No | $0 | TX |
| Prominence Dual (HMO D-SNP) | Prominence Healthfirst OF Florida Inc | T3 | No | $0 | FL |
| Prominence Diabetes and Heart Giveback (HMO C-SNP) | Prominence Healthfirst | T3 | No | $0 | NV |
| Prominence Diabetes and Heart Giveback (HMO C-SNP) | Prominence Healthfirst OF Florida Inc | T3 | No | $0 | FL |
| Prominence Diabetes and Heart Giveback (HMO C-SNP) | Prominence Healthfirst OF Texas | T3 | No | $0 | TX |
| Prominence Diabetes and Heart Care Plus (HMO C-SNP) | Prominence Healthfirst OF Texas | T3 | No | $0 | TX |
| Prominence Diabetes and Heart Giveback (HMO C-SNP) | Prominence Healthfirst OF Texas | T3 | No | $0 | TX |
| Prominence Extra Help (HMO) | Prominence Healthfirst | T3 | No | $4.20 | NV |
| Prominence Extra Help (HMO) | Prominence Healthfirst OF Florida Inc | T3 | No | $4.80 | FL |
| Prominence Extra Help (HMO) | Prominence Healthfirst OF Texas | T3 | No | $4.80 | TX |
| Prominence Extra Help (HMO) | Prominence Healthfirst | T3 | No | $9.50 | NV |
| Select Health Medicare Essential (HMO) | Selecthealth, Inc. | T5 | Yes | $0 | UT |
| Select Health Medicare Essential (HMO) | Selecthealth, Inc. | T5 | Yes | $0 | NV |
| Select Health Medicare Dual (HMO D-SNP) | Selecthealth, Inc. | T5 | Yes | $0 | UT |
| Select Health Medicare Essential (HMO) | Selecthealth, Inc. | T5 | Yes | $0 | UT |
| Select Health Medicare + Kroger (HMO) | Selecthealth, Inc. | T5 | Yes | $0 | NV |
Showing top 50 of 100 plans.
Frequently Asked Questions
Is sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro] covered by Medicare Part D?
Yes, sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro] is covered by 267 Medicare Part D plans (5.3% of all Part D formularies).
What tier is sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro] on Medicare Part D plans?
sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro] averages Tier 4.4 across Part D plans, ranging from Tier 1 to Tier 5.
Does sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro] require prior authorization?
7.1% of Part D formularies require prior authorization for sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro]. Step therapy: 0%. Quantity limits: 7.1%.
How much does Medicare spend on sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro]?
In 2023, total Medicare Part D spending on sucroferric oxyhydroxide 500 MG Chewable Tablet [Velphoro] was $465,812,435, covering 36,082 beneficiaries. The average spend per beneficiary was $12,909.83.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- 0.5 ML filgrastim-sndz 0.6 MG/ML Prefilled Syringe [Zarxio] T4.4
- 0.8 ML filgrastim-sndz 0.6 MG/ML Prefilled Syringe [Zarxio] T4.4
- 168 HR granisetron 0.129 MG/HR Transdermal System [Sancuso] T4.4
- chenodeoxycholate 250 MG Oral Tablet [Ctexli] T4.4
- maralixibat 10 MG Oral Tablet [Livmarli] T4.4
- 0.5 ML nedosiran 160 MG/ML Injection [Rivfloza] T4.4
Similar prior-authorization rate
- paroxetine mesylate 7.5 MG Oral Capsule 7.1% PA
- prednisolone 10 MG Disintegrating Oral Tablet 7.1% PA
- acetohydroxamic acid 250 MG Oral Tablet [Lithostat] 7.1% PA
- mometasone furoate 0.025 MG/ACTUAT / olopatadine hydrochloride 0.665 MG/ACTUAT Metered Dose Nasal Spray [Ryaltris] 7.1% PA
- 3.5 ML paliperidone palmitate 312 MG/ML Prefilled Syringe [Invega] 7% PA
- 5 ML paliperidone palmitate 312 MG/ML Prefilled Syringe [Invega] 7% PA